Running title: Biological capture of CTCs for companion diagnostics. 
Significance of this study
What is already known about this subject?
 The molecular characterization of CTCs based on genetic alterations facilitates the administration of molecular targeted drugs for preventing metastatic progression in individual cancer patient. 
How might it impact on clinical practice in the foreseeable future?
 Because current CTC detection strategies mainly depend on epithelial cell surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs.
 Fluorescent virus-based biological capture system is a promising tool for monitoring genetic alterations in both epithelial and mesenchymal types of CTCs.
INTRODUCTION
The rapid evolution of genetic and genomic technologies in regards to predictive pharmacogenetic biomarkers for molecularly targeted therapies (e.g., monoclonal antibodies and small-molecule tyrosine kinase inhibitors) have resulted in tremendous advances in personalized oncologic treatment 1 . The current commonly used biomarkers include human epidermal growth factor receptor 2 (HER2) for the use of trastuzumab in breast and gastric cancer 2, 3 , KRAS for the use of cetuximab and panitumumab in colorectal cancer 4 , echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK)
for the use of crizotinib, and epidermal growth factor receptor (EGFR) for the use of erlotinib and gefitinib, in non-small cell lung cancer 5, 6 , and BCR-ABL for the use of tyrosine kinase inhibitors in chronic myeloid leukemia 7 . Companion diagnostic assays are designed to accompany specific therapies and help guide selection of patients according to expected drug responses. While the use of these assays has led to a shift in paradigms from disease-based therapeutic regimens to molecular target-based protocols 8, 9 , many of these molecular diagnostic modalities have onerous specimen requirements, such as needle core biopsies or surgical sampling of tumor tissues that can be invasive.
Circulating tumor cells (CTCs), first described in 1869 by Ashworth 10 , are often present in the peripheral blood of patients with advanced cancers. However, as CTCs are very rare within the bloodstream, detection of CTCs can be difficult. The most commonly used CTC detection method is the CellSearch system 11, 12 , which can enrich CTCs using magnetized antibodies that target the major epithelial cell surface marker, epithelial cell adhesion molecule (EpCAM). More recently, genetic analysis of the EGFR gene using the EpCAM-dependent CTC-chip detection system has been described for the surveillance of CTCs in patients with lung cancers 13 . CTCs are thought to contain the metastasis-initiating tumor cells that form metastatic colonies at distant organs 14, 15 , but recent studies have suggested that there are heterogeneous populations that include CTCs with both epithelial and mesenchymal characteristics 16 , which are associated with epithelial-mesenchymal transition (EMT) 17 . Recently, EpCAM-positive and EpCAM-negative CTCs from breast cancer patients have been shown to exhibit high potential to metastasize to the lung and brain, respectively, in nude mice 18, 19 . In colorectal cancer patients, not only captured cytokeratin (CK)-positive
CTCs, but also co-captured CK-negative cells have been shown to possess complex aneuploidy 20 . Moreover, it has been reported that plastin3 (PLS3), which is a novel marker for EMT, was detected in EpCAM-positive and EpCAM-negative CTCs in colorectal cancer patients with distant metastasis 21 . These findings indicate the presence of CTCs without epithelial markers in colorectal cancer patients. Therefore, development of a CTC capture system that functions independent of the epithelial cell marker is required to precisely assess the sensitivity of highly metastatic tumor cells to molecularly targeted drugs.
Epithelial and mesenchymal types of malignant tumor cells possess high telomerase activity to maintain the length of telomere during aberrant cell proliferation, suggesting the potential of the telomerase activity as a general tumor marker 22 and therapeutic target 23 . We previously developed a green fluorescent protein (GFP)-expressing telomerase-specific replication-competent adenovirus (OBP-401, TelomeScan) that drives the adenoviral E1A and E1B genes under the hTERT gene promoter for telomerase-dependent virus replication. OBP-401 enables the visualization of viable epithelial and mesenchymal types of human tumor cells with telomerase activity as GFP-positive cells 24, 25 . OBP-401-mediated GFP labeling is a useful method to detect viable CTCs in patients with gastrointestinal cancers 26, 27 and ovarian cancers 28 . The present study extends on our previous work by exploring the potential of an OBP-401-based biological CTC capture system for the surveillance of genetic mutations in viable CTCs as a novel non-invasive companion diagnostic strategy.
MATERIALS AND METHODS

Cell lines
The human colorectal cancer cell lines, SW480, HCT116 and HT29; the human pancreatic cancer cell line, Panc1; the human lung cancer cell line, A549 and H1299; the human GIST cell line, GIST882; and the human normal esophageal fibroblasts, FEF3, were purchased from the American Type Culture Collection. All cell lines were cultured according to the manufacturer's specifications. There are four types of KRAS gene mutations (G12D, G12V, G12S, G13D) in Panc1, SW480, A549 and HCT116 cells, respectively. HT29 cells have one mutation (V600E) in the BRAF gene, whereas GIST882 cells harbor one mutation (K642E) in the KIT gene. Normal FEF3 cells have no mutations in the KRAS, BRAF or KIT genes.
To obtain the EMT-induced human cancer cells, A549 cells were treated with TGF-β (10 ng/ml) for 72 h. EMT induction was defined as a morphological change to spindle type and a change in the EMT-related marker expression, including downregulation of epithelial markers (EpCAM and E-cadherin) and upregulation of the mesenchymal marker (Ncadherin).
Recombinant adenovirus
OBP-401 is a telomerase-specific replication-competent adenovirus variant, in which the hTERT gene promoter drives the expression of E1A and E1B genes that are linked to an internal ribosome entry site and in which the GFP gene is inserted into the E3 region under a cytomegalovirus (CMV) promoter (figure 1A) [24] [25] [26] . OBP-401 was purified by ultracentrifugation using CsCl step gradients. Viral titers were determined by a plaqueforming assay using 293 cells, and the virus was stored at −80°C.
Immunocytochemical staining
The cells seeded on tissue culture chamber slides were fixed in 4% paraformaldehyde for 15 minutes on ice. The slides were subsequently incubated with the PE-conjugated mouse antiEpCAM antibody (BioLegend, San Diego, CA, USA) for 1 h on ice. Then the slides were analyzed using an inverted fluorescent microscope (Olympus; Tokyo, Japan).
Flow cytometry
The cells (1 × 10 5 cells) were labeled with primary mouse antibodies for EpCAM, E-cadherin, N-cadherin (BioLegend) and CAR for 30 min on ice and were analyzed using flow cytometry (FACS Array; Becton Dickinson, Mountain View, CA, USA).
CTC model
CTC models were established by incubation with tumor cell lines (SW480, HCT116, HT29, Panc1, EMT-induced A549 and GIST882 cells) in 5 ml of blood (containing approximately 3.5 × 10 7 white blood cells) from a healthy volunteer.
DNA extraction from CTC model and clinical samples
The protocol for DNA extraction from the CTC model or clinical samples is shown in figure   2A and 
Gene mutation analysis by direct sequencing
Taq polymerase, forward primer and reverse primer were mixed with eluted DNA solution, and DNA was amplified using the PCR Thermal Cycler. Primer sequences and PCR settings are shown in Supplementary Table S1 . Using the PCR products, the sequence of each gene was analyzed with ABI PRISM 3100 Genetic Analyzer (Life Technologies, Carlsbad, CA, USA).
Gene mutation analysis by ASB-PCR
ASB-PCR for the KRAS and BRAF genes was performed with a primer set of TaqMan Mutation Detection Assays (Applied Biosystems, Foster City, CA, USA), as described in a previous report 29 . This assay amplifies only mutant alleles with mutant-specific primers and prevents the amplification of wild-type alleles using blocking oligonucleotides. Genetic mutations of target genes were analyzed with StepOnePlus™ real-time PCR system (Applied Biosystems). Genotyping Master mix and Mutation Detection Assay were mixed with two sets of eluted DNA solution, and this mixture was applied to real-time PCR analysis. The mutation detection method was customized as follows. The PCR cycle number was set to 70 cycles for the efficient amplification of small copy numbers of target genes. A total cell count was restricted to less than 50 cells/well to prevent non-specific amplification of wild-type alleles. The sensitivity and specificity were analyzed using a mixture of KRAS/BRAF wildtype and mutant cells. Genetic mutation was recognized as positive when the amplification for mutant alleles using specific primer was detected. 
RESULTS
Fluorescent imaging of human cancer cells with differential EpCAM expression
Genetic analysis of OBP-401-labelled GFP-positive cells using direct sequencing
FACS-isolated GFP-positive CTCs at the P3 gate were analyzed genetically by direct sequencing (Supplementary Table 1 purity ratio. KRAS gene mutation could be detected by direct sequencing only in the samples containing more than a 30% purity ratio of SW480 cells ( figure 3B ). Thus, high purity of mutant-type CTCs in heterogeneous populations is necessary for detection of genetic alterations by direct sequencing.
Genetic analysis of OBP-401-labeled GFP-positive cells using ASB-PCR
To further increase the sensitivity to detect genetic alterations in the heterogeneous populations of CTCs, we next evaluated the potential of the Allele-Specific Blocker (ASB)-PCR method using four types of mutation-specific primers for the KRAS or BRAF genes.
Before analyzing the human cancer cells, we confirmed that there was no amplification of PCR products in the human normal fibroblast with wild-type KRAS and BRAF genes or in blood obtained from normal healthy volunteers by ASB-PCR with mutation-specific primers (Supplementary figure 3) .
When we analyzed five human cancer cells mixed with 100 human normal fibroblasts at a purity ratio of approximately 5%, ASB-PCR using all types of primers detected the expected mutations in the GFP-positive cells (Supplementary Table 2 ). In the CTC models When treated with the EMT inducer, transforming growth factor-β (TGF-β), A549 cells showed spindle-shape morphological changes ( figure 4B ) and altered EMT-related biomarker expression, such as EpCAM and E-cadherin downregulation and N-cadherin upregulation ( figure 4C ). In contrast, CAR expression was not affected after TGF- treatment ( figure 4C ) and, therefore, OBP-401 efficiently induced GFP expression in the TGF--treated A549 cells ( figure 4D ). In addition, GIST882 cells were confirmed to be EpCAM-negative ( figure 4E ). When 10 EMT-induced A549 cells were spiked in blood samples, the expected genetic mutation (G12S) in the KRAS gene was detected by direct sequencing and by ASB-PCR analysis (figure 4F-G and Table 1 ). In contrast, the expected KIT gene mutation could be detected at the P3 gate by direct sequencing in the CTC model containing 100 GIST882 cells and KIT, even in EpCAM-negative cells among highly heterogeneous CTC populations.
We applied telomerase-specific OBP-401 to selectively label human neoplastic cells with GFP signals and confirmed its broad infectivity independent of EpCAM expression, which was consistent with observations from our previous reports that OBP-401 induced GFP expression in both epithelial and mesenchymal types of tumor cells 24, 25 . Recent studies have Mutation in KRAS and BRAF genes is highly associated with resistance to the anti-EGFR antibody, cetuximab, in colorectal cancer patients 42, 43 . In fact, the appearance of KRAS gene mutant DNA is associated with resistance to cetuximab in patients with KRAS wildtype colorectal cancers 44 . In colorectal cancer patients, the frequency of the KRAS and BRAF gene mutations is significantly higher in liver metastasis than in primary tumors 45 , and KRAS and BRAF gene mutant status is significantly associated with poor outcomes 46 . These findings suggest that genetic analysis for the KRAS and BRAF gene mutation in CTCs can be used as a "liquid biopsy" to monitor resistance to cetuximab and to predict the metastatic potential in patients with KRAS wild-type colorectal cancers.
It is also worth noting that OBP-401-based biological CTC capture system is applicable to the genetic analysis of CTCs with mesenchymal characteristics, including GISTs and osteosarcomas 25 , although the CellSearch system is also useful for detection of epithelial
CTCs. Approximately 80% of GIST cells harbor a mutation in the KIT gene 30 , which is significantly associated with disease recurrence and poor outcomes 47 . Recently, the small molecule tyrosine kinase inhibitor imatinib has been shown to be effective against KITmutated GIST that is refractory to conventional chemotherapy 48 . In contrast, bone and soft tissue sarcoma cells, which make up one of the most notorious types of malignant mesenchymal tumor, are also detectable as GFP-positive cells by OBP-401 infection 25 .
Frequent lung metastasis has been shown to be a poor prognostic factor in patients with osteosarcoma, but the potential of CTC enumeration in osteosarcoma patients remains to be elucidated. Thus, the characterization of CTCs using the OBP-401-based biological CTC capture system may be a useful strategy for monitoring metastatic progression in patients with GIST or osteosarcomas as well as in those with epithelial malignant tumors.
The combination of the OBP-401-based CTC capture system and genetic analysis using ASB-PCR detected KRAS and BRAF mutations in blood samples obtained from colorectal cancer patients, and these mutations were identical to those seen in the primary tumors. This novel "liquid biopsy" via a simple blood test could be carried out in real time and enables optimized and timely decisions for therapeutic intervention. However, the technology has to be further validated in large clinical studies with defined endpoints. In addition, one limitation of our study was that it was difficult for ASB-PCR to detect uncommon genetic abnormalities. Regardless, when frequently occurring genetic mutations are targeted for the surveillance of CTCs, the ASB-PCR method would be a useful and highly sensitive method for detecting the small number of CTCs with genetic mutations. In contrast, if the identification of genetic traits in highly metastatic CTCs is the main goal, a genomewide approach should be considered for the genetic analysis of CTCs. For example, genomewide transcriptome analysis has been performed to identify a wide range of copy number alterations in the entire CTCs using array-comprehensive genomic hybridization (aCGH) 49 .
Moreover, genetic analysis in single CTC has been recently used to clarify the global gene alterations using aCGH and next-generation sequencing 50, 51 . Thus, the comprehensive analysis of genetic alterations in individual CTCs from cancer patients would provide novel insight into the identification of the genetic signature in association with metastatic progression.
In summary, we established a telomerase-dependent biological CTC capture system for genotyping of epithelial, mesenchymal, and EMT-induced types of CTCs using OBP-401 and 
